


## **MEDICINAL PRODUCTS 2017**



## ARCA biopharma Inc. Rank 24 of 44





## **MEDICINAL PRODUCTS 2017**



## ARCA biopharma Inc. Rank 24 of 44

The relative strengths and weaknesses of ARCA biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ARCA biopharma Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 136% points. The greatest weakness of ARCA biopharma Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 74% points.

The company's Economic Capital Ratio, given in the ranking table, is 18%, being 65% points above the market average of -47%.

Input Variable	Value in 1000 USD
Assets, Current	21,445
Assets, Non-Current	766
General and Administrative Expense	4,265
Goodwill	0
Liabilities, Current	2,396
Liabilities, Non-Current	0
Other Assets	2,352
Other Compr. Net Income	-19
Other Expenses	0
Other Liabilities	39
Other Net Income	0
Other Revenues	169
Property, Plant and Equipment, Net	66
Research and Development	12,348

Output Variable	Value in 1000 USD
Liabilities	2,435
Assets	24,629
Expenses	16,613
Revenues	169
Stockholders Equity	22,194
Net Income	-16,444
Comprehensive Net Income	-16,454
Economic Capital Ratio	18%

